Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06179875 · ClinicalTrials.gov registry record · Phase 3
An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054)
A Phase 3 study, sponsored by Viridian Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 143
- Enrollment target
NCT06179875 is a Phase 3 study that has completed, run by Viridian Therapeutics. The registered enrollment target is 143 participants.
The verdict
NCT06179875, a Phase 3 study, has completed, sponsored by Viridian Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 143 participants
- Enrollment target
Study Summary
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). The primary objectives of this clinical trial are to provide open-label access to VRDN-001 for participants who were previously non-responders at 3 weeks post the fifth IV infusion (i.e., 15 weeks) in the VRDN-001-101 (THRIVE) and VRDN-001-301 (THRIVE-2) pivotal studies and assess the safety and efficacy of VRDN-001 in participants who were previously treated with VRDN-001 or placebo.
Interventions
- DRUG Veligrotug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2025-06-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06179875
The ClinicalTrials.gov registry entry for NCT06179875 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viridian Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Veligrotug is the first listed.
NCT06179875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06179875 about?
NCT06179875 is a clinical study titled "An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054)". The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye d...
What is the current status of trial NCT06179875?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 143 participants. The study started on 2024-01-31. Estimated completion is 2025-06-23.
What interventions are being tested in trial NCT06179875?
The interventions under investigation include: Veligrotug (DRUG).
Who is sponsoring clinical trial NCT06179875?
This trial is sponsored by Viridian Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.